NDAORALCAPSULE
Approved
Mar 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
PONSTEL (mefenamic acid) by Molecular Devices is cyclooxygenase inhibitors [moa]. First approved in 1967.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PONSTEL (mefenamic acid) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce pain and inflammation. It is primarily indicated for the short-term treatment of mild to moderate pain and dysmenorrhea. The drug has been on the market since 1967 and represents a mature, legacy product in the NSAID class.
LOE Approaching
Product faces moderate competitive pressure (score: 30) with limited team expansion opportunity as patent exclusivity erodes.
Mechanism of Action
Cyclooxygenase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study of Soticlestat With Itraconazole and Mefenamic Acid in Healthy Adults
Started Oct 2021
28 enrolled
Healthy Volunteers
Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects
Started Mar 2017
16 enrolled
Diabetes Mellitus
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
Started Jan 1998
337 enrolled
Dysmenorrhea
Career Relevance
PONSTEL offers limited career growth opportunity given its approaching loss of exclusivity and low linked job count. Roles on this product tend to focus on defensive commercial execution, regulatory compliance, and transition planning rather than innovation or expansion.
Worked on PONSTEL at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.